It has been found that PTPN3 inhibition significantly contributes to enhancing the activation and functions of activated lymphocytes, and has anti-cancer effects on small-cell lung cancer (SCLC) and large-cell neuroendocrine carcinoma (LCNEC) [21, 22]. The gene discussed is PTPN3; the disease is large cell neuroendocrine carcinoma.